For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 108,448 | |||
| General and administrative | 34,451 | |||
| Total operating expenses | 142,899 | |||
| (loss) income from operations | -142,899 | |||
| Interest and other income, net | 11,779 | |||
| (loss) income before income tax expense | -131,120 | |||
| Net (loss) income | -131,120 | |||
| Basic EPS | -3.05 | |||
| Diluted EPS | -3.05 | |||
| Basic Average Shares | 42,976,024 | |||
| Diluted Average Shares | 42,976,024 | |||
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)